논문KCI 등재
Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
참고문헌 (9)
관련 논문AI추천
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”Qile Wang, Qingwang Ye, Wei Feng대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”Dae Won Jun, Hee Yeon Kim, Miyoung Choi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”Dae Won Jun, Hee Yeon Kim, Miyoung Choi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Ma대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classificationHan Ah Lee대한내과학회 · The Korean Journal of Internal Medicine2024 · 제39권 제6호Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”Jeayeon Park, Su Jong Yu대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호
이 간행물의 다른 논문 (84건)
Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossipp. 32-50Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Yichong Jiang, Yue Wangpp. 51-75Precision medicine and nucleotide-based therapeutics to treat steatotic liver diseaseAndrea Caddeo, Stefano Romeopp. 76-93Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseJasmohan S. Bajaj, Jeremy Burton, Antonio Gil-Gómez, Huma Saeed, Juan Pablo Arab, Luis Antonio Díaz, Manuel Romero-Gomez, Marco Arrese, Mohammad Qasim Khanpp. 94-111Alcohol-associated liver disease: Natural history, management and novel targeted therapiesHugo López-Pelayo, Edilmar Alvarado-Tapias, Ana Clemente-Sánchez, Ramón Bataller, Jordi Gratacós-Ginès, Elisa Posepp. 112-133